Literature DB >> 10818593

Enrichment methods for mutation detection.

C D Gocke1, F A Benko, M S Kopreski, D B Evans.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 10818593     DOI： 10.1111/j.1749-6632.2000.tb06587.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  7 in total

1.  EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer.

Authors:  S Kamel-Reid; G Chong; D N Ionescu; A M Magliocco; A Spatz; M Tsao; X Weng; S Young; T Zhang; D Soulieres
Journal:  Curr Oncol       Date:  2012-04       Impact factor: 3.677

Review 2.  Suppressor Mutants: History and Today's Applications.

Authors:  David E Bautista; Joseph F Carr; Angela M Mitchell
Journal:  EcoSal Plus       Date:  2021-12-15

Review 3.  PCR-based methods for the enrichment of minority alleles and mutations.

Authors:  Coren A Milbury; Jin Li; G Mike Makrigiorgos
Journal:  Clin Chem       Date:  2009-02-06       Impact factor: 8.327

Review 4.  Liquid biopsy for detection of actionable oncogenic mutations in human cancers and electric field induced release and measurement liquid biopsy (eLB).

Authors:  Michael Tu; David Chia; Fang Wei; David Wong
Journal:  Analyst       Date:  2016-01-21       Impact factor: 4.616

5.  Extendable blocking probe in reverse transcription for analysis of RNA variants with superior selectivity.

Authors:  Tho H Ho; Kien X Dang; Susanna Lintula; Kristina Hotakainen; Lin Feng; Vesa M Olkkonen; Emmy W Verschuren; Tuomas Tenkanen; Caj Haglund; Kaija-Leena Kolho; Ulf-Hakan Stenman; Jakob Stenman
Journal:  Nucleic Acids Res       Date:  2014-11-05       Impact factor: 16.971

Review 6.  RAS testing in metastatic colorectal cancer: advances in Europe.

Authors:  J Han J M Van Krieken; Etienne Rouleau; Marjolijn J L Ligtenberg; Nicola Normanno; Scott D Patterson; Andreas Jung
Journal:  Virchows Arch       Date:  2015-11-16       Impact factor: 4.064

7.  Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients.

Authors:  Petra Martin; Carolyn J Shiau; Maria Pasic; Ming Tsao; Suzanne Kamel-Reid; Stephanie Lin; Roxana Tudor; Susanna Cheng; Brian Higgins; Ronald Burkes; Matilda Ng; Saroosh Arif; Peter M Ellis; Stacy Hubay; Sara Kuruvilla; Scott A Laurie; Jing Li; David Hwang; Anthea Lau; Frances A Shepherd; Lisa W Le; Natasha B Leighl
Journal:  Br J Cancer       Date:  2016-02-18       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.